New collaboration with Gubra on obesity treatment

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonistsObesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options availableNew collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseasesGubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news